Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant α-N-acetylglucosaminidase and relationship with Sanfilippo phenotype in an attenuated patient  by Yogalingam, Gouri et al.
Mucopolysaccharidosis type IIIB: characterisation and expression of
wild-type and mutant recombinant K-N-acetylglucosaminidase and
relationship with San¢lippo phenotype in an attenuated patient
Gouri Yogalingam a;*, Birgit Weber a, Judith Meehan b, John Rogers b,
John J. Hopwood a
a Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, 72 King William Road,
North Adelaide, SA 5006, Australia
b Victorian Clinical Genetics Service, Royal Children’s Hospital, Parkville, Victoria 3052, Australia
Received 22 May 2000; received in revised form 20 July 2000; accepted 20 July 2000
Abstract
Mucopolysaccharidosis type IIIB (MPS-IIB) is a lysosomal storage disorder characterised by the defective degradation of
heparan sulfate due to a deficiency of K-N-acetylglucosaminidase (NAG). The clinical severity of MPS-IIIB ranges from an
attenuated to severely affected Sanfilippo phenotype. This paper describes the expression and characterisation of wild-type
recombinant NAG and the molecular characterisation of a previously identified R297X/F48L compound heterozygous MPS-
IIIB patient with attenuated Sanfilippo syndrome. We have previously shown R297X to be the most common mutation in a
cohort of Dutch and Australian patients, occurring at a frequency of approximately 12.5%. To date F48L has only been
described in the proband. To determine the contribution of each mutation to the overall clinical phenotype of the patient,
both mutant alleles were engineered into the wild-type NAG cDNA and expressed in Chinese hamster ovary cells. The wild-
type NAG and F48L mutant alleles were also retrovirally expressed in MPS-IIIB skin fibroblasts. Residual NAG activity and
the stability and maturation of immunoprecipitated NAG were determined for wild-type NAG and mutant NAG. The
combined biochemical phenotypes of the two NAG mutant alleles demonstrated a good correspondence with the observed
attenuated Sanfilippo phenotype of the patient. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mucopolysaccharidoses are a group of 11 in-
herited lysosomal storage diseases (LSD) which re-
sult from de¢ciencies of speci¢c lysosomal enzymes
that are required for the lysosomal degradation of
glycosaminoglycans (GAG). The mannose-6-phos-
phate (M6P) moieties on lysosomal enzymes serve
as high-a⁄nity ligands for binding to M6P receptors
in the trans-Golgi network (TGN). Binding with
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Abbreviations: MPS-IIIB, mucopolysaccharidosis type IIIB;
NAG, K-N-acetylglucosaminidase; TGN, trans-Golgi network;
WT-NAG, wild-type NAG; GAG, glycosaminoglycan; FCS, foe-
tal calf serum; M6P, mannose-6-phosphate (M6P); CHO-KI,
Chinese hamster ovary cells ; DMEM, Dulbecco’s modi¢ed Ea-
gle’s medium; F12, Ham’s F12 medium
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M6P receptors permits lysosomal enzymes to be seg-
regated from proteins destined for secretion or trans-
port to other intracellular compartments. The ligand-
receptor complex is then transported from the TGN
via a clathrin-coated vesicle to an acidi¢ed endoso-
mal compartment where the M6P receptor and lyso-
somal enzyme dissociate. Further processing of the
enzyme occurs in the lysosome. The M6P receptor is
either recycled from the endosome back to the Golgi
for further targeting of endogenous de novo synthe-
sised lysosomal enzymes or transported to the plas-
ma membrane where it functions to internalise exog-
enous lysosomal enzymes [1].
Mucopolysaccharidosis type III (MPS-III), also
known as San¢lippo syndrome, results from the ab-
sence of one of four lysosomal enzymes that are se-
quentially involved in the degradation of heparan
sulfate: heparan N-sulfatase (MPS-IIIA), K-N-acetyl-
glucosaminidase (NAG, MPS-IIIB), acetylCoA:
K-glucosaminide acetyl-transferase (MPS-IIIC) or
N-acetylglucosamine 6-sulfatase (MPS-IIID) [2]. An
absence of any one of these enzymes leads to the
lysosomal accumulation and urinary excretion of
heparan sulfate and the clinical onset of San¢lippo
syndrome. In Australia the combined prevalence of
MPS III is 1:66 000 births [3].
The clinical presentation of MPS-III is character-
ised by severe central nervous system degeneration
resulting in progressive mental retardation and is
often combined with hyperactivity and aggressive be-
haviour. The San¢lippo phenotype of MPS-III
varies, ranging from severe to attenuated. Unlike
most of the other MPS, the somatic features of
MPS-III, which involve skeletal pathology, hepato-
splenomegaly and joint sti¡ness, are relatively mild
and observed mainly in older patients. Often the lack
of somatic involvement leads to di⁄culty in diagnos-
ing patients with MPS-III [2].
The cDNA sequence for NAG has been cloned
and characterised [4,5] with the gene localised to
17q21.1. Molecular characterisation of MPS-IIIB pa-
tients has resulted in the identi¢cation of several mu-
tations in the NAG gene [5^11]. The high degree of
molecular heterogeneity re£ects the wide clinical var-
iability observed with MPS-IIIB. Certain mutations
show a higher prevalence. For example, the stop mu-
tation R297X accounted for 12.5% of mutant alleles
in a recent molecular study of 40 MPS IIIB patients
(10 out of 80 alleles) [9]. Zhao et al. [11] reported a
severely a¡ected homozygous R297X/R297X San¢-
lippo patient [11]. At 13 years of age the patient
was severely demented, despite bone marrow trans-
plantation. A severely a¡ected homozygous R297X/
R297X San¢lippo patient, diagnosed at 6 years of
age, has also been reported [9]. These observations
suggest that R297X is associated with a severe San-
¢lippo phenotype when inherited in a homozygous
fashion [9,11]. The presence of an attenuated San¢-
lippo phenotype in a F48L/R297X compound het-
erozygous patient suggests that the F48L allele is
associated with an attenuated phenotype [9]. In this
study the relationship between genotype, cell bio-
chemistry and clinical phenotype in a F48L/R297X
compound heterozygous San¢lippo patient was eval-
uated by individually characterising the two muta-
tions, F48L and R297X. As an initial step towards
developing gene therapy for MPS-IIIB, we also ret-
rovirally transduced MPS-IIIB skin ¢broblasts with
the NAG cDNA and demonstrated correction of the
enzymatic and biochemical (GAG storage) defect.
2. Materials and methods
2.1. Case report: patient S.B.
Recently the genotype of the proband was deter-
mined to be compound heterozygous for R297X and
F48L [9].
A 31-year-old male, born in 1968, presented at
18 months of age with failure to thrive, developmen-
tal delay, hepatomegaly and diarrhoea. He had three
normal siblings. At age 3 years he had coarse hair, a
protuberant abdomen, soft hepatomegaly and nor-
mal facies. His weight was less than the third percen-
tile. A provisional diagnosis of glycogen storage dis-
ease was made.
Liver function testing and a skeletal survey were
both normal. Liver biopsy was consistent with a ly-
sosomal storage disorder likely to be MPS-III. A
bone marrow biopsy and leucocytes showed lysoso-
mal inclusions. A urinary screen for mucopolysac-
charides (Royal Children’s Hospital, Melbourne)
was normal. A course of plasma infusions, then cur-
rently in vogue, was undertaken for 4 months. While
this acutely shrank the liver and spleen, it was overall
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without clinical e¡ect. He remained intellectually de-
layed while displaying hyperactive aggressive behav-
iour but no regression.
As his course was atypical for MPS, repeat liver,
skin and bone marrow biopsies were performed at
age 8 years. At this stage there was persisting hepa-
tomegaly, coarse hair and developmental delay. The
liver biopsy was again consistent with a diagnosis of
MPS-III with some progression to liver cirrhosis.
The bone marrow inclusions persisted but a urinary
screen for mucopolysaccharides remained negative.
Skeletal survey showed minor vertebral changes.
Aged 8, IQ testing put him in the 4- to 5-year range
with a wide scatter. At this time he was living in a
residential setting for the intellectually disabled. He
attended a special school and was able to acquire
some skills. Later he moved to a smaller institutional
setting. Here he had a two-wheeler bike and used to
ride freely around the neighbourhood to undertake a
message or shopping. Whilst obviously intellectually
delayed, he had a good memory for names and
events and had become quite sociable.
At 12 years of age (1980) samples were sent to the
Women’s and Children’s Hospital in North Ade-
laide, South Australia for high-resolution electropho-
resis of urine [12] which showed a signi¢cant eleva-
tion of heparan sulfate, consistent with San¢lippo
syndrome. In contrast, his total urinary glycosami-
noglycan content (19 mg/mmol creatinine) was just
above the upper limit of normal for his age group (3^
17 mg/mmol creatinine). These results emphasise the
high incidence of false negative results in the urinary
screening test for heparan sulfate by some methods
leading to di⁄culty in diagnosing patients with MPS-
III.
MPS-IIIB was diagnosed on the basis of the de¢-
ciency of NAG. Over the ensuing 8 years the patient
did not show the rapid developmental deterioration
associated with severe San¢lippo syndrome. His liver
was no longer enlarged and his joints were normal.
The third decade of life was characterised by a
phase of intellectual deterioration and aggressive be-
haviour. He had an early loss of coordination aged
21 years and outbursts of rage, which improved after
treatment with Thioridazine. Aged 22 years his mem-
ory deteriorated as did his self-care skills. He could
no longer ride his bike and slept a lot regardless of
Thioridazine dosage.
An echocardiogram performed aged 23 years was
normal. Aged 23 years he underwent an inguinal
hernia repair without complication. Nine months lat-
er he began to lose weight and develop paranoid
delusions. He was noted to be prematurely ageing
and engaging in meaningless babble. From the age
of 24 years he seemed to lose his sense of direction
and self care skills further deteriorated. This skill
loss, along with memory loss became more profound
from the age of 27 years. Presently aged 31, he has
had a progressive loss of physical skills, co-ordina-
tion and muscle wasting manifested by frequent falls
and inability to climb stairs. He is increasingly som-
nolent alternating with occasional erratic behaviour.
He has poor short-term memory and no longer has
self-care skills. He remains in residential care and still
enjoys a reasonable quality of life.
2.2. Mutagenesis
The missense mutations F48L and R297X [9] were
introduced into the WT NAG cDNA construct,
pBluel33+4 [4] by using a QuickChange site-directed
mutagenesis kit (Stratagene). The oligonucleotides
used for each mutagenesis reaction are summarised
in Table 1. Brie£y, each polymerase chain reaction
(PCR) (50 Wl volume) contained 50 ng of pBluel33+4
template, 125 ng of each oligonucleotide primer (Ta-
ble 1), 1Ureaction bu¡er, 1 Wl of dNTP mix, 1UQ
bu¡er (Qiagen) and 2.5 units of Pfu Turbo DNA
polymerase. Each PCR was then denatured at 95‡C
for 30 s and then subjected to 12 cycles of the follow-
ing conditions: 95‡C for 30 s, 55‡C for 1 min and
68‡C for 12 min. Ten units of DpnI restriction en-
zyme was then added to each reaction and incubated
at 37‡C for 1 h. Five Wl of each DpnI digested PCR
was then transformed into Epicurian Coli XLI-Blue
Supercompetent cells as described by the supplier
(Stratagene). Clones containing the mutated se-
quence were identi¢ed by allele-speci¢c oligonucleo-
tide hybridisation (Table 1) and subsequently se-
quenced to ensure that no other changes other than
the desired mutation had been introduced into the
NAG cDNA sequence. pBluel33+4F48L and
pBluel33+4R297X were digested with BstEII and
BamHI. The inserts containing the mutagenised
NAG sequences were then sub-cloned into the WT
NAG expression construct pcDNANAG [4] digested
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with the same restriction endonucleases. Clones con-
taining the mutagenised NAG sequence were identi-
¢ed by allele speci¢c oligonucleotide hybridisation
and designated pcDNAF48L and pcDNAR297X.
2.3. Cell culture
Unless otherwise stated, all cell culture reagents
were purchased from Gibco-BRL. Chinese hamster
ovary cells (CHO-KI) were grown in Ham’s F12
(F12) supplemented with 10% (v/v) bovine foetal
calf serum (FCS, CSL Ltd), and antibiotics (penicil-
lin, 100 U/ml and streptomycin sulfate, 100 Wg/ml).
Skin ¢broblasts, Bosc 23 cells [13] and PA317 cells
[14] were grown in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) supplemented with FCS (10% v/v)
and antibiotics.
2.4. Electroporation of CHO-KI cells
CHO-KI cells were electroporated with 30 Wg of
pcDNAF48L, pcDNAR297X, and pcDNANAG as
previously described [15]. Electroporated cells were
selected with 0.75 mg/ml geneticin (G418) for 2 weeks
resulting in the appearance of approximately 300
G418-resistant colonies per electroporation. G418-re-
sistant mass-cultures of electroporated cells were
used for the determination of NAG activity and im-
munoprecipitation (see below).
2.5. Retroviral vector construction
The WT NAG cDNA or mutagenised NAG se-
quence was excised from pcDNANAG and
pcDNAF48L with HindIII and EcoRV and sub-
cloned into pLNCX [16] digested with HindIII and
StuI. The presence of the NAG cDNA in each con-
struct was con¢rmed by restriction enzyme analysis.
Constructs containing the cDNA in the correct ori-
entation were isolated and designated pLNCNAG
and pLNCF48L.
2.6. Generation of amphotropic LNCNAG and
LNCF48L virus
The retroviral constructs pLNCNAG and
pLNCF48L (25 Wg) were transfected into the eco-
tropic virus packaging cell line Bosc-23 [13] using
Lipofectamine transfection reagent (Gibco-BRL).
Medium containing transiently expressed ecotropic
retrovirus was harvested 48^96 h after transfection,
¢ltered (0.2-Wm ¢lter) and used to infect PA317 cells
[14] in the presence of 4 Wg/ml polybrene. PA317 cells
were exposed to four 12-h cycles of freshly harvested
ecotropic virus infection, then subcultured 1:3 and
grown in the presence of 1 mg/ml G418 for 2 weeks.
2.7. Retrovirus transduction of MPS-IIIB skin
¢broblasts
Sixteen-hour-conditioned medium was harvested
from G418-resistant mass-cultures of PA317/
LNCF48L and PA317/LNCNAG, ¢ltered (0.2-Wm ¢l-
ter) and used to infect MPS-IIIB (R297X/R297X ho-
mozygous) skin ¢broblasts (SF 4657, 70% con£uent
in 75-cm2 £asks) in the presence of 4 Wg/ml poly-
brene. MPS-IIIB ¢broblasts were exposed to ¢ve
cycles of freshly harvested amphotropic virus infec-
tion. Each virus exposure was approximately 16^24
h. After the ¢nal virus exposure the transduced cells
were fed with growth medium until they reached
con£uence. Transduced ¢broblasts were then sub-
cultured 1:3 into three 75-cm2 £asks and grown in
the presence of 0.3 mg/ml G418 for 3 weeks.
2.8. Determination of NAG activity
Skin ¢broblast and CHO-KI cultures were grown
Table 1
Sequence of oligonucleotide primers that were used for the quick change mutagenesis of WT-NAG cDNA sequence
Primer pair Sequence Sense or antisense Position
F48L-1 CCGCGGCCGACCTCTCCGTGTCG + 232^254
F48L-2 CGACACGGAGAGGTCGGCCGCGG 3 254^232
R297X-1 CGGAGCCTCTTCCTGTGAGAGCTGATCAAAG + 975^1006
R297X-2 CTTTGATCAGCTCTCACAGGAAGAGGCTCCG 3 1006^975
The positions of primers in the NAG sequence are according to Fig. 3 of Weber et al. [4].
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to con£uence in 75-cm2 £asks. At 3 days post-con-
£uence the cells were harvested with trypsin-versene
(CSL Ltd), washed with PBS, resuspended in 150 Wl
0.5 M NaCl/0.02 M Tris (pH 7) and subjected to
seven cycles of freeze^thaw in a slurry of dry ice
and ethanol. Lysates were clari¢ed by microcentrifu-
gation at 13 000 rpm for 3 min. Clari¢ed ¢broblast
lysates and CHO-KI lysates were assayed for NAG
activity using the £uorogenic substrate 4-methylum-
belliferyl-2-acetomido-2-deoxy-K-D-glucopyranoside
(Calbiochem) [17] and normalised for protein con-
centration as determined by the BioRad protein as-
say (BioRad).
2.9. Analysis of GAG storage
Normal ¢broblasts (SF 4858), MPS-IIIB ¢bro-
blasts (R297X/R297X homozygous; SF 4657),
LNCF48L and LNCG737R transduced MPS-IIIB ¢-
broblasts were grown to con£uence in 25-cm2 £asks
and then metabolically labelled for 24 h with 10 WCi/
ml Na352 SO4 (570 mCi/mmol; DuPont NEN) in anti-
biotic-free Ham’s F12 supplemented with 10% (v/v)
FCS. Labelled cells were then harvested with trypsin-
versene (CSL Ltd) and transferred to new 25-cm2
£asks containing DMEM supplemented with 10%
FCS and antibiotics (penicillin, 100 U/ml and strep-
tomycin sulfate, 100 Wg/ml) and grown for a further
5 days. Some £asks of labelled MPS-IIIB ¢broblasts
were exposed to 24-h-conditioned medium collected
from LNCNAG transduced MPS-IIIB ¢broblasts in
the presence or absence of 5 mM M6P (Sigma) dur-
ing the 5-day chase period. Cell lysates were prepared
and assayed for total cell protein, 35S radioactivity,
L-hexosaminidase and NAG activity.
2.10. Immunoprecipitation of NAG
CHO-KI cells and G418-resistant mass-cultures of
CHOR297X, CHOF48L and CHONAG were grown
to con£uence in 75-cm2 £asks and then metabolically
labelled for 30 min with 100 WCi/ml EXPRE35S35S
[35S] protein labelling mix (1175 Ci/mmol, DuPont,
NEN) in cysteine-methionine-free DMEM (ICN Bio-
medicals) supplemented with L-glutamine and FCS.
Labelled cells were rinsed with medium and then
chased with growth medium (Ham’s F12 supple-
mented with FCS and antibiotics) for 4, 11 or 16 h.
At each chase time one 75-cm2 £ask of labelled cells
were harvested by treatment with trypsin-versene, re-
covered by centrifugation, resuspended in 10 ml PBS
and then centrifuged again. The cell pellet was resus-
pended in 10 ml of 1Usolubilisation bu¡er (PBS
containing 1% w/v sodium deoxycholate, 0.1% w/v
sodium dodecyl sulfate (SDS), 0.5% Nonidet P-40)
and incubated for 24 h at 4‡C. Prior to immunopre-
cipitation with NAG polyclonal antisera, growth me-
dium and solubilised cell lysates were pre-cleared as
follows. Seventy Wl of polyclonal CHO-KI antiserum
(prepared by CSL Ltd) was added to each medium
or solubilised lysate sample and incubated at 4‡C
overnight. Equilibrated pansorbin cells (140 Wl, Cal-
biochem) were added to each sample, incubated at
4‡C for a further 6 h and then sedimented by cen-
trifugation. The pre-cleared supernatant was then
immunoabsorbed using 40 Wl of unpuri¢ed rabbit
polyclonal antisera raised against recombinant
NAG (Weber et al., submitted). After an overnight
incubation at 4‡C, 70 Wl of equilibrated pansorbin
cells were added to each sample and incubated at
4‡C for 6 h. NAG^IgG^pansorbin complexes were
Table 2
Expression of F48L-NAG, R297X-NAG and WT-NAG in CHO-KI cells
Intracellular NAG
(nmol/h per mg)
Secreted NAG
(nmol/h per ml)
Intracellular L-hex
(nmol/min per mg)
CHO-KI 7.81 þ 0.37 4.32 þ 0.24 19.31 þ 0.95
CHOF48L 8.23 þ 0.44 4.53 þ 0.18 21.76 þ 0.36
CHOR297X 7.85 þ 0.17 4.67 þ 0.18 16.49 þ 0.16
CHONAG 159.63 þ 4.76 13.20 þ 0.27 19.67 þ 0.35
CHO-KI cells were electroporated with the mutagenised or WT-NAG cDNA. Twenty-four-hour-conditioned medium and cell lysates
prepared from con£uent G418-resistant mass cultures were assayed for NAG activity or L-hexosaminidase (L-hex) activity using £uo-
rogenic substrates. Results are expressed as the mean þ S.D. (n = 3).
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pelleted by centrifugation, washed by microcentrifu-
gation/resuspension with two 1-ml volumes of solu-
bilisation bu¡er, once with 1 ml of water and then
resuspended in 50 Wl sample bu¡er. Samples were
boiled for 5 min, centrifuged at 12 000Ug for 1 min
to pellet Pansorbin cells, and the supernatant ana-
lysed via SDS^polyacrylamide gel electrophoresis
(PAGE) and autoradiography.
3. Results
3.1. Expression of F48L-NAG, R297X-NAG and
WT-NAG in CHO-KI cells
G418-resistant mass-cultures of CHO-KI cells
over-expressing F48L-NAG, R297X-NAG and WT-
NAG were assayed for NAG activity using the £uo-
rogenic substrate as described in Section 2. Control
CHO-KI cells contained a signi¢cant amount of en-
dogenous NAG activity (7.81 nmol/h per mg total
cell protein, Table 2). CHO-KI cells electroporated
with pcDNAF48L (CHOF48L) and pcDNAR297X
(CHOR297X) contained NAG activities similar to
control CHO-KI cells (8.23 nmol/h per mg and
7.85 nmol/h per mg, respectively). Medium harvested
from control CHO-KI, CHOF48L and CHOR297X
cells contained comparable NAG activities as well
(Table 2). In contrast, in G418-resistant mass-cul-
tures of CHO-KI cells electroporated with pcDNA-
NAG (CHONAG), signi¢cant amounts of NAG ac-
tivity toward the £uorogenic substrate were
measured (159 nmol/h per mg, Table 2). Medium
harvested from CHONAG cells contained 13.2
nmol/h per ml of NAG activity (Table 2). The activ-
ity of the lysosomal enzyme L-hexosaminidase was
not a¡ected by the expression of F48L-NAG,
R297X-NAG and WT-NAG in CHO-KI cells
(Table 2).
C
Fig. 1. Stability of intracellular (A) and secreted (B) R297X-
NAG, F48L-NAG and WT-NAG in CHO-KI cells. Control
CHO-KI cells (C), CHOR297X cells (R297X), CHOF48L
(F48L) and CHONAG (NAG) cells were grown to con£uence
in 75-cm2 tissue-culture £asks and metabolically labelled with
EXPRE35S35S [35S] protein labelling mix for 30 min. The label-
ling medium was then removed and cells were chased in growth
medium for 0.5 h (CHO-KI and CHOR297X cells), or 4, 11
and 16 h (CHOF48L and CHONAG cells). At each time point
labelled cells (A) and growth medium (B) were harvested, im-
munoprecipitated and analysed via SDS^PAGE and autora-
diography. The molecular masses are indicated with arrows and
were calculated by comparison with C-14 methylated standards
run alongside the gel.
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3.2. Immunoprecipitation of R297X-NAG,
F48L-NAG and WT-NAG
Control CHO-KI cells and G418-resistant mass-
cultures of CHOR297X were metabolically labelled
with EXPRE35S35S [35S] protein labelling mix for
30 min and then chased for 30 min or 4 h. At the
30-min chase time point 35S-labelled R297X-NAG
immunoprecipitated from CHOR297X cell lysates
was detected as a truncated 34 kDa polypeptide
(Fig. 1A) which was no longer detectable at the 4-h
chase time point (result not shown). No 35S-labelled
R297X NAG was detectable in the chase medium
(result not shown).
G418-resistant mass-cultures of CHOF48L and
CHONAG were metabolically pulse-labelled with
EXPRE35S35S [35S] protein labelling mix for 30 min
and then chased for varying lengths of time (4, 11 or
16 h). At the 4-h chase time point, 35S-labelled WT-
NAG immunoprecipitated from CHONAG cell ly-
sates migrated under reducing conditions as a pre-
cursor 80 kDa polypeptide. At the 11- and 16-h
chase time points intracellular WT-NAG was succes-
sively reduced to 78.5 and 77 kDa, respectively (Fig.
1A). At the 4-, 11- and 16-h chase time points, the
secreted form of 35S-labelled WT-NAG was detected
as a precursor 89 kDa polypeptide (Fig. 1B). In con-
trast, 35S-labelled F48L-NAG immunoprecipitated
from CHOF48L cell lysates was only detected as a
80 kDa precursor polypeptide (Fig. 1A). F48L-NAG
did not appear to be cleaved to the intracellular ma-
ture 77 kDa form or be secreted into the medium
(Fig. 1A,B).
3.3. Expression of F48L-NAG and WT-NAG in
MPS-IIIB skin ¢broblasts
MPS-IIIB ¢broblasts were exposed to ¢ve cycles of
Table 3
Analysis of GAG storage in retrovirus transduced MPS-IIIB ¢broblasts
Intracellular NAG
(nmol/h per mg cell protein)
Secreted NAG
(nmol/h per ml)
Intracellular L-hex
(nmol/min per mg)
35S Radioactivity
(cpm/mg cell protein)
Normal ¢broblasts 8.815 þ 0.175 0.5 þ 0.3 46.9 þ 2.2 6,975 þ 991
MPS-IIIB ¢broblasts n.d. n.d. 68.1 þ 0.5 84,351 þ 510
MPS-IIIB/LNCF48L 1.86 þ 0.07 n.d. 48.3 þ 0.8 55,711 þ 1576
MPS-IIIB/LNCNAG 49.6 þ 0.21 46.6 þ 0.4 49.7 þ 0.5 12,461 þ 1230
MPS-IIIB skin ¢broblasts were retrovirally transduced with F48L-NAG (MPS-IIIB/LNCF48L) or WT-NAG (MPS-IIIB/LNCNAG) as
described in Section 2. Control normal ¢broblasts, control MPS-IIIB ¢broblasts or gene-transduced ¢broblasts were metabolically la-
belled for 24 h with Na352 SO4 and then passaged for a further 3 days. Cell lysates were prepared and assayed for total protein,
35S ra-
dioactivity, L-hexosaminidase (L-hex) activity and NAG activity. Twenty-four-hour-conditioned medium was also collected from each
cell line and assayed for NAG activity. Results are expressed as the mean þ S.D. (n = 3). n.d., not detected.
Table 4
Partial correction of GAG storage in MPS-IIIB ¢broblasts with MPS-IIIB/LNCNAG conditioned medium
NAG
(nmol/h per mg)
L-Hexosaminidase
(nmol/min per mg)
35S Radioactivity
(cpm/mg cell per protein)
Normal ¢broblasts 25.12 þ 2.23 84.3 þ 14.7 3915 þ 182
MPS-IIIB ¢broblasts 0.101 þ 0.025 94.0 þ 12.7 47988 þ 3328
MPS-IIIB ¢broblasts+MPS-IIIB/LNCNAG
conditioned medium
0.388 þ 0.048 80.7 þ 4.4 33305 þ 1518
MPS-IIIB ¢broblasts+MPS-IIIB/LNCNAG
conditioned medium+5 mM M6P
0.057 þ 0.012 94.5 þ 4.5 48874 þ 3861
Con£uent triplicate cultures (25-cm2 £asks) of normal ¢broblasts (row 1) and MPS-IIIB ¢broblasts (rows 2^4) were labelled for 24 h
with Na352 SO4 then passaged for a further 5 days. Some groups of labelled MPS-IIIB ¢broblasts (rows 3 and 4) were also exposed to
conditioned medium (46.6 nmol/h per ml) collected from LNCNAG-transduced MPS-IIIB ¢broblasts in the absence (row 3) or pres-
ence (row 4) of 5 mM M6P during the 5-day chase period. Cell lysates were prepared and assayed for total protein, 35S radioactivity,
L-hexosaminidase and NAG activity. Results are expressed as the mean þ S.D. (n = 3).
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LNCF48L or LNCNAG virus infection and then pas-
saged for 3 weeks in the presence of 0.3 mg/ml G418.
The storage of undegraded, sulfated GAGs in MPS-
IIIB ¢broblasts was analysed by measuring the intra-
cellular retention of radioactivity in cells metabol-
ically labelled with Na352 SO4. In this experiment
R297X/R297X homozygous skin ¢broblasts obtained
from a severely a¡ected MPS-IIIB patient (patient 30
of Table 4, Weber et al. [9]) contained no detectable
NAG activity and approximately 12 times more in-
tracellular 35S radioactivity than normal control ¢-
broblasts (Table 3). We have made the assumption
that the majority of accumulated intracellular 35S
radioactivity in MPS-IIIB ¢broblasts corresponds
to the stored GAG, heparan sulfate. Transduction
of MPS-IIIB ¢broblasts with LNCNAG virus re-
sulted in the clearance of 35S-labelled GAG storage
to amounts approaching normal (Table 3). The
amount of intracellular NAG activity in LNCNAG-
transduced ¢broblasts was elevated 5.6-fold when
compared with normal ¢broblasts (Table 3). In con-
trast, the amount of intracellular NAG activity in
LNCF48L transduced MPS-IIIB ¢broblasts was sig-
ni¢cantly reduced (1.86 nmol/h per mg) and corre-
sponded to 3.75% of NAG activity in LNCNAG-
transduced MPS-IIIB ¢broblasts (Table 3). The re-
sidual amount of NAG activity in LNCF48L-trans-
duced MPS-IIIB ¢broblasts resulted in the partial
clearance of 35S-labelled GAG storage (55 711 cpm/
mg, Table 3) when compared with 35S-labelled GAG
storage in control MPS-IIIB ¢broblasts (84 351 cpm/
mg, Table 3). The expression of the lysosomal en-
zyme L-hexosaminidase was not a¡ected by the ret-
roviral-mediated gene expression of F48L-NAG and
WT-NAG.
Conditioned medium harvested from LNCNAG-
transduced MPS-IIIB ¢broblasts contained 46.6
nmol/h per ml of NAG activity (Table 3). To deter-
mine whether this secreted form of NAG was being
correctly processed, two groups of MPS-IIIB ¢bro-
blasts were incubated with 24-h-conditioned medium
harvested from LNCNAG-transduced ¢broblasts
(46.6 nmol/h per ml, Table 3). Incubation with con-
ditioned medium from LNCNAG-transduced MPS-
IIIB ¢broblasts resulted in the partial clearance of
35S-labelled GAG storage and the detection of only
a small amount of endocytosed NAG activity in
MPS-IIIB ¢broblasts (Table 4). The presence of
5 mM M6P in the culture medium prevented the
uptake of recombinant NAG by MPS-IIIB ¢bro-
blasts and clearance of 35S-labelled GAG storage
(Table 4).
3.4. Analysis of I-cell plasma
Plasma from I-cell patients contained elevated
amounts of NAG and L-hexosaminidase when com-
pared with normal control plasma samples. How-
ever, acid phosphatase, which is targeted to the lyso-
some independently of the mannose-6-phosphate
receptor pathway, was not elevated in I-cell plasma
samples when compared with normal control plasma
samples (Table 5).
4. Discussion
4.1. Expression of R297X-NAG and F48L-NAG
In this study we investigated the relationship be-
tween genotype, cellular biochemistry and clinical
phenotype in a F48L/R297X compound heterozy-
gous MPS-IIIB patient with an attenuated San¢lippo
phenotype. Molecular characterisation of this com-
pound heterozygous MPS-IIIB patient was compli-
cated by the presence of two mutant NAG alleles,
which together cause an attenuated San¢lippo phe-
notype (see Section 2.1). To determine the e¡ect of
each mutation on NAG synthesis, sub-cellular distri-
bution and activity, both mutant alleles were engi-
Table 5
Analysis of L-hexosaminidase, NAG and acid phosphatase activity in I-cell plasma
L-Hexosaminidase (nmol/min per ml) NAG (nmol/h per ml) ACP (nmol/min per ml)
Control plasma (n = 3) 5.83 þ 1.58 19.7 þ 6.3 21.67 þ 5.78
I-cell plasma (n = 3) 96.1 þ 10.73 316.93 þ 32.36 21.33 þ 3.56
Plasma from normal controls (37, 38, 39) or I-cell patients (285, 256, 257) were assayed for L-hexosaminidase, NAG or acid phospha-
tase (ACP) using £uorogenic substrates. Results are expressed as the mean þ S.D. (n = 3)
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neered into the wild-type NAG cDNA and ex-
pressed. The R297X allele displayed no detectable
NAG activity when expressed in CHO-KI cells and
was observed only as a 34 kDa truncated polypeptide
that was rapidly degraded. Skin ¢broblasts obtained
from a homozygous R297X/R297X patient con-
tained very low levels of NAG activity (0.101 nmol/
h per mg total protein, Table 4) and a 12-fold ele-
vated level of 35S-labelled GAG storage when com-
pared with normal ¢broblasts. The low levels of
NAG activity detected in these ¢broblasts may be
due to bovine NAG activity derived from the foetal
calf serum present in the culture medium or alterna-
tively may be due to a small amount of translational
read-through of the R297X mutant allele. The highly
elevated levels of 35S-labelled GAG storage in homo-
zygous R297X/R297X skin ¢broblasts are consistent
with the clinically severe phenotype associated with
the R297X allele [9,11].
When over-expressed in CHO-KI cells and ana-
lysed via immunoprecipitation, F48L-NAG was de-
tected as a 80 kDa precursor polypeptide that was
not cleaved to the mature 77 kDa form or secreted
into the medium. Furthermore, the 80 kDa F48L-
NAG precursor polypeptide was partially degraded
over the 16-h chase period (Fig. 1A). These results
suggest that the F48L missense mutation a¡ects the
processing and stability of NAG. The F48L precur-
sor polypeptide may correspond to newly synthesised
protein that is selectively retained in the endoplasmic
reticulum due to incorrect folding and is subse-
quently degraded. Alternatively, some F48L-NAG
may be synthesised as an unstable precursor poly-
peptide that is transported to the lysosome and
rapidly degraded in the hydrolytic environment.
When expressed via retroviral-mediated gene transfer
in homozygous R297X/R297X MPS-IIIB skin ¢bro-
blasts, intracellular F48L-NAG activity corre-
sponded to 3.75% of NAG activity levels in WT-
NAG-transduced MPS-IIIB ¢broblasts. This residual
level of NAG activity was su⁄cient to metabolise
34% of intracellular 35S-labelled GAG storage sug-
gesting that some F48L-NAG is being correctly
sorted to the lysosomal compartment. The residual
level of F48L-NAG activity in the lysosomes of
F48L-NAG-transduced MPS-IIIB ¢broblasts and
subsequent partial turnover of GAG is consistent
with the attenuated clinical phenotype associated
with the F48L allele in patient SB (see Section
2.1).
4.2. Expression of WT-NAG
The WT-NAG cDNA was over-expressed in
CHO-KI cells and immunoprecipitated with a rabbit
polyclonal antibody to recombinant NAG. To char-
acterise WT-NAG in terms of its maturation, newly
synthesised radiolabelled NAG was immunoprecipi-
tated after varying lengths of chase time. Intracellu-
lar NAG was detected as a precursor polypeptide of
80 kDa which was successively cleaved to a 78.5 kDa
intermediate polypeptide and a mature 77 kDa poly-
peptide over a 16-h chase time (Fig. 1A). This is in
agreement with previous studies in which native
NAG has been puri¢ed to homogeneity from a num-
ber of di¡erent tissues ([4,11,18]). The delayed pro-
cessing of newly synthesised NAG in CHO-KI cells
may be expression system-speci¢c rather than NAG
speci¢c as we have also observed slow processing of
other lysosomal enzymes in CHO-KI cells [19].
As an initial step toward gene therapy in animal
models for MPS-IIIB, a retroviral construct that
contained WT-NAG cDNA sequence was made
(pLNCNAG) and used to transduce cultured MPS-
IIIB skin ¢broblasts. The pLNCNAG construct was
designed to express NAG from the cytomegalovirus
immediate^early (CMV) promoter and the neomy-
cin-resistance gene from the viral LTR promoter.
Amphotropic LNCNAG virus was generated and
used to transduce MPS-IIIB skin ¢broblasts. G418-
resistant mass cultures of LNCNAG-transduced
MPS-IIIB ¢broblasts displayed correction of the en-
zymatic and storage phenotype associated with MPS-
IIIB (Table 3). These results suggest that LNCNAG
gene-corrected MPS-IIIB ¢broblasts express func-
tional NAG that is correctly processed and targeted
to the lysosome. Although there was a ¢vefold ele-
vated level of NAG activity in LNCNAG-transduced
MPS-IIIB ¢broblasts when compared with normal
control ¢broblasts, 35S-labelled GAG storage was
not completely normalised. This could be due to
slightly di¡erent growth rates of the normal control
¢broblasts and LNCNAG-transduced MPS-IIIB ¢-
broblasts, di¡erent rates of incorporation of the
35S-label into GAGs or di¡erent amounts of GAG
production by the two groups of cells.
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LNCNAG-transduced MPS-IIIB ¢broblasts se-
creted detectable levels of NAG activity into the cul-
ture medium (46.6 nmol/h per ml, Table 3). This
conditioned medium was used in a cross-correction
experiment to determine whether the secreted form
of WT-NAG was correctly mannose-6-phosphorylat-
ed. Incubation of MPS-IIIB skin ¢broblasts for an
extended chase period (5 days) with conditioned me-
dium from LNCNAG-transduced MPS-IIIB ¢bro-
blasts resulted in only a small amount of endocy-
tosed intracellular NAG activity which was
su⁄cient to partially reduce 35S-labelled GAG stor-
age (Table 4). No clearance of 35S-labelled GAG
storage was observed with shorter chase periods (3
days, results not shown). In the presence of 5 mM
M6P no reduction in 35S-labelled GAG storage was
observed. These results suggest that the majority of
recombinant WT-NAG secreted from LNCNAG-
transduced MPS-IIIB ¢broblasts is not mannose-6-
phosphorylated. Only a small proportion (0.36%) of
WT-NAG secreted from LNCNAG-transduced
MPS-IIIB ¢broblasts is correctly phosphorylated.
This small amount of secreted, phosphorylated
WT-NAG can be endocytosed by a second popula-
tion of MPS-IIIB skin ¢broblasts via the M6P recep-
tor pathway and be correctly targeted to the lyso-
some (Table 4).
We have not observed weak phosphorylation of
other secreted recombinant lysosomal enzymes ex-
pressed in CHO-KI cells or in patient cell lines
([15,19^21]). When directly compared with another
recombinant lysosomal enzyme over-expressed in
CHO-KI cells, N-acetylgalactosamine-4-sulfatase
(CHO4S), the M6P receptor-mediated uptake of
CHONAG into cultured skin ¢broblasts was consid-
erably reduced (Weber et al., unpublished results).
Furthermore, in previous cross-correction experi-
ments using N-acetylgalactosamine-4-sulfatase gene
transduced MPS-VI skin myoblasts, 8.9% (0.664
pmol/min) of the total N-acetylgalactosamine-4-sul-
fatase secreted from the gene-corrected myoblasts
(7.45 pmol/min) was endocytosed by a second pop-
ulation of MPS-VI myoblasts via the M6P receptor
pathway [22]. In contrast, in this study only 0.36%
(1.19 nmol/h) of the total NAG secreted from
LNCNAG-transduced MPS-IIIB ¢broblasts (329
nmol/h) was endocytosed by a second population
of MPS-IIIB ¢broblasts via the M6P receptor path-
way (Table 4). Weak phosphorylation of secreted
rNAGLU expressed in HeLa cells has also been ob-
served (G. Yogalingam, unpublished results). These
results suggest that weak phosphorylation of secreted
WT-NAG is NAG-speci¢c rather than expression
system-speci¢c. The causative factors which lead to
poor mannose-6-phosphorylation of secreted WT-
NAG were not investigated further in this study.
We did not determine whether the poor phosphory-
lation of WT-NAG is due to only a small degree of
the enzyme being post-translationally phosphorylat-
ed or due to the enzyme being phosphorylated nor-
mally but susceptible to very rapid dephosphoryla-
tion. These results suggest that the use of secreted
recombinant WT-NAG in future enzyme and gene
therapy protocols will be severely limited due to its
small degree of mannose-6-phosphorylation.
The importance of targeting lysosomal enzymes
via the M6P receptor pathway is demonstrated in
patients with I-cell disease. Due to a de¢ciency of
UDP-N-acetylgalactosamine phosphotransferase, I-
cell patients are unable to transfer M6P moieties
onto carbohydrate side chains of lysosomal enzymes.
The presence of elevated NAG activity in I cell plas-
ma samples (Table 5) indicates that normally the
intracellular form of WT-NAG is correctly phos-
phorylated and targeted to the lysosome. The results
obtained in this study have demonstrated that
LNCNAG-transduced MPS-IIIB ¢broblasts express
intracellular WT-NAG that is correctly targeted to
the lysosome and capable of turning over stored
GAG. Although the secreted form of WT-NAG is
poorly mannose-6-phosphorylated, these initial stud-
ies do highlight the potential for using the correctly
mannose-6-phosphorylated, intracellular form of re-
combinant WT-NAG in future gene therapy treat-
ments for MPS-IIIB patients.
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